

DAFTAR PUSTAKA

- Adiputra, I. M. S., Trisnadewi, N. W., Oktaviani, N. P. W., & Munthe, S. A. (2021). *Metodologi Penelitian Kesehatan*.
- Aleid, A., & Zenteno-cuevas, R. (2024). *Association Between Diabetes Mellitus – Tuberculosis and the Generation of Drug Resistance*. 1–24.
- Alex, A. (2024). *Scoping Review: Gambaran Radiografis Lesi Paru Pada Tuberkulosis Resisten Obat di Indonesia*. 5, 3615–3620.
- Annexes, W. (2022). *consolidated guidelines on tuberculosis*.
- Ayalign, B., Negash, M., Genetu, M., & Wondmagegn, T. (2019). *Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis*. 2019. <https://doi.org/10.1155/2019/6196532>
- Bartholomay, P., Pinheiro, R. S., Dockhorn, F., Pelissari, D. M., & Araújo, W. N. De. (2021). Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis. *BMC Infectious Diseases*, 1–13. <https://doi.org/10.1186/s12879-021-06756-7>
- Cecile, D. I., Alex, N. N. S., Joëlle, N. D., Cedric, N. S., Noemy, C. T., Irene, W. G., & Mfongouot, P. (2022). *Risk Factors Associated to Multidrug - Resistant Tuberculosis in Patients Attending the Deido District Hospital of Douala – Cameroon*. <https://doi.org/10.4103/ijmy.ijmy>
- Chairani, A., Hadiwardjo, Y. M., Kristanti, M., & Prabarini, I. R. S. (2023). Pentingnya Edukasi Gizi Seimbang dan Pengenalan Isi Piringku pada Siswa Remaja SMA Islam. *SEGARA: Jurnal Pengabdian Kepada Masyarakat*, 1(2), 60–64. <https://doi.org/10.33533/segara.v1i2>
- Chandrasekaran, P. (2017). *Malnutrition : Modulator of Immune Responses in Tuberculosis*. 8(October), 1–8. <https://doi.org/10.3389/fimmu.2017.01316>
- Clemencia, R., Zuñiga, G., Victoria, B., Vite, A. De, Suarez, A. A., Karina, D., Carrasco, E., Santos, E. G., Eufemia, I., Aquise, L., & Sánchez, I. C. (2025). *Educational Level Mediates the Relationship Between Knowledge and Preventive Practices in Multidrug-Resistant Tuberculosis Patients*. 1–21.
- Dhanyalayam, D., Thangavel, H., Lizardo, K., Desai, J. V, Nagajyothi, J. F., Dhanyalayam, D., Thangavel, H., Lizardo, K., Desai, J. V, & Nagajyothi, J. F. (2025). *during sub-acute Mycobacterium tuberculosis infection*. 13(12).
- Dlatu, N., Faye, L. M., Sineke, N., Apalata, T., Sciences, H., Africa, S., Sciences, H., Africa, S., & Dlatu, N. (2025). *Predictors of drug-resistant TB outcomes : Body mass index , HIV , and comorbidities*. 1–7.

- Fajarwati, I., Handayani, D., & Burhan, E. (2019). *Diabetes Mellitus Increases Risk of Multi-Drug Resistant Tuberculosis in Jakarta, Indonesia*. A5153–A5153. https://doi.org/10.1164/ajrcm-conference.2019.199.1_meetingabstracts.a5153
- Feldman, C., Theron, A. J., Cholo, M. C., & Anderson, R. (2024). *Cigarette Smoking as a Risk Factor for Tuberculosis in Adults: Epidemiology and Aspects of Disease Pathogenesis*. 1–16.
- Franquet, T., & Chung, J. (2019). *Imaging of Pulmonary Infection*. 65–77. <https://doi.org/10.1007/978-3-030-11149-6>
- Gando, G., Id, A. F., Koula, K., Jolly, B. L., Mossoro-kpinde, C. D., & Id, A. M. (2023). *Effectiveness of Xpert MTB / RIF and the Line Probe Assay tests for the rapid detection of drug-resistant tuberculosis in the Central African Republic*. <https://doi.org/10.1371/journal.pgph.0001847>
- Garcia, U., Benito-vicente, A., Jebari, S., & Larrea-sebal, A. (2020). *Pathophysiology of Type 2 Diabetes Mellitus*. 1–34.
- Gupta, M., Srikrishna, G., Klein, S., & Bishai, W. R. (2023). *immune responses in tuberculosis*. 43(8), 640–656. <https://doi.org/10.1016/j.it.2022.06.004>. Genetic
- Huang, D., Wang, Y., Wang, Y., & Liang, Z. (2020). *The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis*. 9(2), 152–162. <https://doi.org/10.21037/apm.2020.02.16>
- Irawan, B., & Murti, B. (2022). *Meta-Analysis: Smoking and Proverty as Risk Factors of Tuberculosis Multidrug Resistance*. 07, 284–298.
- Jang, J. G., & Chung, J. H. (2020). *Diagnosis and treatment of multidrug-resistant tuberculosis*. 37(4), 277–285.
- Kemenkes. (2019). Permenkes Nomor 25 Tahun 2016. *Sustainability (Switzerland)*, 11(1), 1–14. http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI
- Kemenkes. (2020). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberculosis. In *Early Human Development* (Vol. 83, Issue 1). <https://doi.org/10.1016/j.earlhumdev.2006.05.022>
- Kemenkes. (2020). *Temukan TB Obati Sampai Sembuh Penatalaksanaan Tuberculosis Resisten Obat di Indonesia*.

- Kemenkes. (2023). *Laporan Program Penanggulangan Tuberkulosis Tahun 2023*.
- Kemenkes. (2023). *Pemantuan Status Gizi Pada Lansia* (Vol. 2, Issue 2).
- Kemenkes RI. (2021). Surat Edaran Nomor HK.02.02/III.1/936/2021 Direktorat Jendral Pencegahan dan Pengendalian Penyakit tentang Perubahan Alur Diagnosis dan Pengobatan Tuberkulosis di Indonesia. In *Kementerian Kesehatan Republik Indonesia* (pp. 1–8). https://tbindonesia.or.id/wp-content/uploads/2020/05/LAB_Surat-Edaran-Perubahan-Alur-Diagnosis-dan-Pengobatan-TB-di-Indonesia-936.pdf
- Kemenkes RI. (2023). *Buku Pegangan Operasional Pengobatan Tuberkulosis Resistan Obat dengan Paduan BPAL/M*.
- Kementerian Kesehatan Republik Indonesia. (2024). *Petunjuk Teknis Penatalaksanaan TB RO di Indonesia*.
- Kevelaitiene, K., Davidaviciene, V. ., & Danila, E. (2025). *Tuberculosis Treatment Failure : What are the risk factors ? A comprehensive literature review*. 20. <https://doi.org/10.5826/mrm.2025.1030>
- Kumar, N. P., & Babu, S. (2023). *Impact of diabetes mellitus on immunity to latent tuberculosis infection*. January, 1–7. <https://doi.org/10.3389/fcdhc.2023.1095467>
- Li, S., Liang, Y., & Hu, X. (2022). Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus. *BMC Infectious Diseases*, 1–8. <https://doi.org/10.1186/s12879-022-07831-3>
- Lolong, D. B., Irianto, J., Kusriani, I., & Tarigan, I. U. (2025). *actors contributing to multidrug-resistant tuberculosis among sputum culture-positive pulmonary tuberculosis patients in Indonesia: A cross-sectional study*.
- Lv, H., Zhang, X., Zhang, X., Bai, J., You, S., Li, X., Li, S., & Wang, Y. (2024). *Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019*. 1–9.
- Lyu, M., Wang, D., Zhao, J., Yang, Z., Chong, W., Zhao, Z., Ming, L., & Ying, B. (2020). International Journal of Infectious Diseases A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus. *International Journal of Infectious Diseases*, 97, 69–77. <https://doi.org/10.1016/j.ijid.2020.05.080>
- Maghfiroh, I. L., Pradita, P. E., Samantha, H., Kesehatan, F. I., Lamongan, U. M., Sakit, R., Lamongan, M., & Timur, J. (2025). *Journal of Language and Health*. 6(1), 89–98.

- Maison, D. P. (2022). Tuberculosis pathophysiology and anti-VEGF intervention. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 27, 100300. <https://doi.org/10.1016/j.jctube.2022.100300>
- Mamesah, M. M., Kepel, B. J., & Niode, N. jane. (2024). *An Analysis of the Relationship between Factors Causing Multi- Drug Resistant Tuberculosis (Mdr-Tb) in the Minahasa Regency Area*. <https://doi.org/10.35960/vm.v17i2.1500>
- Mansoori, N., Pahlavanzadeh, B., & Atarjalali, M. (2025). Risk factors associated with multidrug-resistant tuberculosis in areas with a moderate tuberculosis burden. *International Health*, 17(2), 186–194. <https://doi.org/10.1093/inthealth/ihae039>
- Maulida, D. H., Mauli, I., Dewi, W., Santoso, P., Cahyadi, A. I., Kusumawati, M., & Kulsum, I. D. (2024). Prevalensi dan Karakteristik Pasien Tuberkulosis Paru Resisten Obat (TB-RO) dengan Diabetes Melitus Tipe 2 di Klinik TB-RO Rumah Sakit Umum Pusat Dr. Hasan Sadikin, Bandung. *Prevalensi dan Karakteristik Pasien Tuberkulosis Paru Resisten Obat (TB-RO) dengan . Jurnal Penyakit Dalam Indonesia*, 11(1). <https://doi.org/10.7454/jpdi.v11i2.1550>
- Mvelase, N. R., & Mlisana, K. (2019). *Evolving rifampicin and isoniazid resistance in a high multidrug- - resistant and extensively drug- - resistant tuberculosis region : a retrospective data analysis*. <https://doi.org/10.1136/bmjopen-2019-031663>
- Nikmawati, S. (2024). *Gambaran Pasien Tuberkulosis Multidrug Resistance (TB-MDR) yang Menjalani Pengobatan di RSUD M . Natsir Selama Periode Tahun 2021-2024*.
- Nono, V. N., Nantia, E. A., Mutshembele, A., Teagho, S. N., Willy, Y., Simo, K., Takong, B. S., Djeugoue, Y. J., Assolo, Y. P., Ongboulal, S. M., Awungafac, S. N., Eyangoh, S., Mensah, E., Makhado, N. A., Flore, V., & Donfack, D. (2025). *Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon*. <https://doi.org/10.1186/s12866-025-03816-9>
- Nurhakim, A. D., Mashoedojo, & Harfiani, E. (2020). Faktor Apa yang Mempengaruhi Rendahnya Tingkat Pengobatan Tuberkulosis di Lagoa Jakarta? What Factors Affect Low Rates of Tuberculosis Treatment in Lagoa Jakarta? *Jurnal Ilmiah Kesehatan Masyarakat*, 12, 110–117.
- Omona, K., & Opiyo, A. M. (2023). *Assessment of risk factors associated with multi-drug resistant tuberculosis (MDR-TB) in Gulu regional referral hospital*. 23(3).

- Pakaya, D., Anwar, S., Fitriana, Y., Trisiyambudi, R., Ruruktipa, D. S., Muliadi, M. Y., Gunawan, F. I., Histologi, D., Kedokteran, F., Tadulako, U., Anatomi, D., Kedokteran, F., Tadulako, U., Kedokteran, P. S., & Tadulako, U. (2024). *Potensi rosuvastatin sebagai agen anti fibrotik: kajian in vivo struktur alveolaris paru dan jumlah sel mast tikus model fibrosis*. 6(2), 765–770.
- Perhimpunan Dokter Paru Indonesia. (2021). Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. In *Perhimpunan Dokter Paru Indonesia* (Vol. 001, Issue 2014).
- PERKENI. (2021). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021*. 46. www.ginasthma.org.
- Restrepo, B. I. (2017). *Diabetes and tuberculosis*. 4(6), 1–19. <https://doi.org/10.1128/microbiolspec.TNMI7-0023-2016>.Diabetes
- Rissaadah, S. (2025). *Glycemic Profile and Clinical Treatment in Patients with Diabetes Mellitus-Tuberculosis : An Update Scoping Review*. January.
- Rocha, D., Viveiros, M., Saraiva, M., & Osorio, N. (2021). *The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem*.
- Rossini, N. D. O., Vinicius, M., & Dias, B. (2023). *Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line drugs*. 1(suppl 2), 1–17.
- Rumende, C. M. (2018). *Risk Factors for Multidrug-resistant Tuberculosis*. 50(1), 1–2.
- Rumende, C. M. (2018). Risk Factors for Multidrug-resistant Tuberculosis. *Acta Medica Indonesiana*, 50(1), 1–2. https://scholar.ui.ac.id/en/publications/risk-factors-for-multidrug-resistant-tuberculosis?utm_source=chatgpt.com
- Saktiawati, A. . I., & Subronto, Y. . (2018). *Influence of Diabetes Mellitus on the Development of Multi Drug Resistant-Tuberculosis in Yogyakarta*. 148(5), 591–593. <https://doi.org/10.1055/s-2008-1048255>
- Sapra, A., & Bhandari, P. (2023). *Diabetes*. <https://www.ncbi.nlm.nih.gov/books/NBK568711/>
- Septafianty, R., Widyoningroem, A., Yamin, M. S. S., & Setiawati, R. (2018). *Comparison of Chest X-Ray Findings between Primary and Secondary Multidrug Resistant Pulmonary Tuberculosis Ricky*. 903–910.
- Shibeshi, W., Sheth, A. N., Admasu, A., Berha, A. B., Negash, Z., & Yimer, G. (2019). *Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia : a*

retrospective cohort study. 1–10.

- Sichen, L., Rui, W., Yue, Y., Xin, L., Youbin, C., & Ze, T. (2023). *Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in Northeast China.* September, 1–7. <https://doi.org/10.3389/fphar.2023.1263726>
- Sinha, A., Klebe, R., Rekart, M. L., Alvarez, J. L., Skrahina, A., Yatskevich, N., Solodovnikova, V., Viatushka, D., Parpieva, N., Safaev, K., Liverko, I., Tigay, Z., Moe, S., Khristusev, A., Allamuratova, S., Mirzabaev, S., Achilov, M., Samieva, N., Lachenal, N., ... Saunders, M. J. (2025). The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings — A Prospective Cohort Study in Belarus and Uzbekistan. *Clinical Infectious Diseases*, 81(4), 838–845. <https://doi.org/10.1093/cid/ciaf035>
- Song, Q., Zhang, G., Jiang, H., Ren, Y., & Lu, X. (2016). *Imaging Features of Pulmonary CT in Type 2 Diabetic Patients with Multidrug-Resistant Tuberculosis.* 1–11. <https://doi.org/10.1371/journal.pone.0152507>
- Song, W. M., Shao, Y., Liu, J. Y., Tao, N. N., Liu, Y., Zhang, Q. Y., Xu, T. T., Li, S. J., Yu, C. B., Gao, L., Cui, L. L., Li, Y. F., & Li, H. C. (2019). Primary drug resistance among tuberculosis patients with diabetes mellitus: A retrospective study among 7223 cases in China. *Infection and Drug Resistance*, 12, 2397–2407. <https://doi.org/10.2147/IDR.S217044>
- Sugiyono. (2023). *Metode Penelitian Kuantitatif Kualitatif dan R&D* (Sutopo (ed.); Kedua). ALFABETA.
- Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., Pavkov, M. E., Ramachandaran, A., Wild, S. H., James, S., Herman, W. H., Zhang, P., Bommer, C., Kuo, S., Boyko, E. J., & Magliano, D. J. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice*, 183, 1–23. <https://doi.org/10.1016/j.diabres.2021.109119>
- Suni, N. S. P. (2024). Tantangan Penanggulangan Tuberkulosis di Indonesia. *Pusat Analisis Keparlemenan Badan Keahlian Setjen DPR RI*, 2. [https://berkas.dpr.go.id/pusaka/files/isu_sepekan/Isu Sepekan---III-PUSLIT-Maret-2024-1957.pdf](https://berkas.dpr.go.id/pusaka/files/isu_sepekan/Isu%20Sepekan---III-PUSLIT-Maret-2024-1957.pdf)
- Tunstall, T., Phelan, J., Eccleston, C., Clark, T. G., & Furnham, N. (2021). *Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages.* 8(July). <https://doi.org/10.3389/fmolb.2021.619403>

- Ulfahimayati, U., Medison, I., & Mizarti, D. (2020). Diabetes Mellitus Tipe 2 sebagai Faktor Predisposisi dan Komorbid Tuberkulosis Multi Drug Resisten Primer. *Jurnal Kedokteran YARSI*, 28(2), 041–050. <https://doi.org/10.33476/jky.v28i2.1422>
- Wang, Z., Hou, Y., Guo, T., Jiang, T., & Xu, L. (2023). *Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China. 2019.*
- WHO. (2020). *consolidated guidelines on tuberculosis.*
- WHO. (2025). *WHO operational handbook on tuberculosis Module 4 : treatment and care.*
- World Health Organization. (2024). *Global Tuberculosis Report 2024.*
- World Health Organization. (2024). *WHO consolidated guidelines on tuberculosis Module 3 : Rapid diagnostics for tuberculosis detection.*
- Wu, L., Chen, N., & Xia, D. (2025). *Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus. January*, 1–11. <https://doi.org/10.3389/fmed.2025.1516207>
- Xi, Y., Zhang, W., Qiao, R., & Tang, J. (2022). *Risk factors for multidrug-resistant tuberculosis : A worldwide systematic review and meta-analysis.* 1–15. <https://doi.org/10.1371/journal.pone.0270003>
- Xu, G., Hu, X., Lian, Y., & Li, X. (2023). *Diabetes mellitus affects the treatment outcomes of drug-resistant tuberculosis : a systematic review and meta-analysis.* 1–13.
- Xu, G., Liu, H., Jia, X., Wang, X., & Xu, P. (2021). Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: The phenomenon of drug resistance is complex. *Tuberculosis*, 128. <https://doi.org/10.1016/j.tube.2021.102083>
- Yuwono, A., Id, S., Id, C. P., Santoso, P., & Lestari, B. W. (2021). *Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia : A retrospective cohort study.* 1–13. <https://doi.org/10.1371/journal.pone.0246284>
- Zahid, M. (2025). *Effect of glycemic control on tuberculosis treatment outcomes among patients with tuberculosis and diabetes mellitus : A systematic review and meta-analysis.* 749–762. <https://doi.org/10.1111/tmi.14140>